1
|
Hikin LJ, Coombes G, Rice-Davies K, Couchman L, Smith PR, Morley SR. Post mortem blood bromazolam concentrations and co-findings in 96 coronial cases within England and Wales. Forensic Sci Int 2024; 354:111891. [PMID: 38043498 DOI: 10.1016/j.forsciint.2023.111891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 11/13/2023] [Accepted: 11/21/2023] [Indexed: 12/05/2023]
Abstract
Bromazolam is a newly emerging benzodiazepine drug which is not licensed for medicinal use. It may be sourced as a New Psychoactive Substance (NPS) for its desired effects or be consumed unknowingly via counterfeit Xanax® or Valium® preparations. As part of our Coronial workload, we observed an increase in the detection of bromazolam from September 2021 to November 2022. We report a series of 96 cases in which bromazolam was quantitated by high resolution accurate mass - mass spectrometry (HRAM - MS) in post-mortem blood. The mean (SD) post-mortem blood bromazolam concentration from our case series was 64.6 ( ± 79.4) µg/L (range <1-425 µg/L). Routine toxicological screening results have also been reported; the most commonly encountered drugs taken in combination with bromazolam were cocaine, gabapentinoids and diazepam. In 48% of cases at least one further designer benzodiazepine drug was also present (etizolam, flualprazolam, flubromazolam, flubromazepam). It is essential that laboratories providing toxicological investigations are aware of the limitations of their assays; and inclusion of bromazolam within targeted screening panels using LC-MS/MS is encouraged. Bromazolam has not been associated with death in isolation from resulting toxic concentrations; however, it is likely to enhance adverse clinical effects when taken in combination with stimulant and/or centrally-acting depressant drugs (poly-drug deaths). Bromazolam, similar to other benzodiazepines, may also impair cognition and decision making skills.
Collapse
Affiliation(s)
- L J Hikin
- University Hospitals Leicester, Leicester Royal Infirmary, Leicester, UK.
| | - G Coombes
- Analytical Services International Ltd, London, UK
| | - K Rice-Davies
- University Hospitals Leicester, Leicester Royal Infirmary, Leicester, UK
| | - L Couchman
- Analytical Services International Ltd, London, UK
| | - P R Smith
- University Hospitals Leicester, Leicester Royal Infirmary, Leicester, UK
| | - S R Morley
- University Hospitals Leicester, Leicester Royal Infirmary, Leicester, UK
| |
Collapse
|
2
|
Zakout S, Johnson H, Coombes G, Mootoo R, Hickey S, Unsworth J, Smith F, Stevens S, Smith E. AB0332 An audit to examine whether there is a correlation between levels of anti-cyclic citrullinated peptide (CCP) antibody titres and joint findings on musculoskeletal ultrasound scan in rheumatoid arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
3
|
Johnston SRD, Chia S, Kilburn LS, Gradishar WJ, Cameron D, Dodwell D, Ellis P, Howell A, Im YH, Coombes G, Piccart M, Dowsett M, Bliss J. Abstract P2-14-01: Fulvestrant vs exemestane for treatment of metastatic breast cancer in patients with acquired resistance to non-steroidal aromatase inhibitors – a meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-14-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Optimal endocrine treatment (trt) for post-menopausal women with ER+ advanced breast cancer (ABC) progressing on or following a non-steroidal (NS) aromatase inhibitor (AI) is unclear. The EFECT study showed no difference in efficacy between the steroidal antiestrogen fulvestrant (F) & steroidal AI exemestane (E) in this setting (HR = 0.96, 95%CI: 0.82, 1.13; p = 0.65). Pre-clinical data suggest F may be more effective in a low estrogen environment. SoFEA investigated F combined with anastrozole (F+A) in patients (pts) with acquired resistance to previous AI compared with F alone & F alone vs. E. The combination of F+A was no better than F (HR = 1.00, 95%CI: 0.83, 1.21; p = 0.98) nor F alone better than E (HR = 0.95, 95%CI: 0.79, 1.14; p = 0.56); the lack of added benefit for F+A is consistent with previous 1st-line studies that have assessed this combination versus A alone (FACT & SWOG-S0226).
Methods: SoFEA is a multi-center partially blinded randomized phase III study postmenopausal women were allocated to F plus A (F+A n=243), F plus placebo (n = 231) or E (n = 249). Similarly, EFECT is a randomized, double-blind, placebo controlled, multi-center phase III trial of F (n = 351) versus E (n = 342) in postmenopausal women (see table). However, given the differences in prior endocrine therapy/responsiveness within SoFEA & EFECT populations, an individual pt meta-analysis combining data from SoFEA & EFECT will be conducted enabling exploration of putative effects within specific pt subgroups to establish evidence in support, or not, of a pt subgroup sensitive to F at the dose used in these trials. Subgroups to be analysed include receptor status, visceral involvement, AI sensitivity, age, NSAI setting & time on NSAI.
Results: 723 pts (480 in F & E) were enrolled from 82 UK & 4 South Korean centers (03/2004-04/2010) in SoFEA. 693 pts were enrolled from 138 centers worldwide (08/2003-11/2005) in EFECT. Trt was well tolerated in both trials; serious adverse events were rare. The meta-analysis will be conducted in July 2012 & results presented.
Conclusion: Combining individual pt data from SoFEA & EFECT via meta-analysis will provide definitive clinical information on pt's response to F at the dose used in these studies, in particular whether certain pts with acquired resistance to NSAI do experience benefit of use of this antiestrogen as opposed to E.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-14-01.
Collapse
Affiliation(s)
- SRD Johnston
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Chia
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - LS Kilburn
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - WJ Gradishar
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - D Cameron
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - D Dodwell
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - P Ellis
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Howell
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Y-H Im
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - G Coombes
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Piccart
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Dowsett
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - J Bliss
- The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | | |
Collapse
|
4
|
Dowsett M, Leary A, Evans A, A'Hern R, Bliss J, Sahoo R, Detre S, Hills M, Haynes B, Harper-Wynne C, Bundred N, Coombes G, Smith IE, Johnston S. Abstract PD07-07: Prediction of antiproliferative response to lapatinib by HER3 in an exploratory analysis of HER2-non-amplified (HER2−) breast cancer in the MAPLE presurgical study (CRUK E/06/039). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-pd07-07] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aim: To identify pretreatment biomarker predictors of Ki67 response to lapatinib in women with HER2− primary breast cancer.
Background: Lapatinib is an EGFR/HER2 inhibitor. Its clinical use is restricted to HER2 overexpressing disease. The MAPLE (Molecular Antiproliferative Predictors of Lapatinib's Effects) presurgical window of opportunity study of lapatinib vs placebo was conducted in women with HER2-amplified (HER2+) or HER2− primary disease. Ki67 (primary end-point) was reduced by a geomean 46% (95%CI 23–63%, p = 0.002) and 27% (95%CI 8–42%, p = 0.008) in HER2+ and HER2− disease, respectively (Leary et al, AACR 2012). We have now assessed whether predictive biomarkers of the antiproliferative response in HER2− disease could be identified.
Methods: 121 primary breast cancer patients were randomized (3:1) to 14 days of 1500mg/d lapatinib or placebo before surgery. Biopsies were taken before treatment and at surgery. Ki67 responders were defined as having a >/=50% reduction in Ki67 compared to baseline (Ellis, P et al, Breast Cancer Res Treat 1998, 48, 107). ER, PgR, HER2, EGFR, pAKT, pERK1/2 (nuclear and cytoplasmic), stathmin and apoptosis (TUNEL) were assessed by IHC (+FISH for HER2[all cases]) and scored visually by continuous methods. HER2, HER3, epiregulin (epir), amphiregulin (amphir) and neuregulin (neur) were assessed by qrtPCR.
Results: Three of the 121 patients were excluded because of inadequate biopsy material. Ninety-one of the remaining 118 patients received lapatinib: 7/19 (37%) HER2+ cases and 10/72 (14%) HER2− cases were Ki67 responders. Thus while the proportion of Ki67 responders was higher for HER2+ disease there was a similar or higher absolute number of responders with HER2− disease. All of the following relates to patients with HER2− disease. None of the pretreatment levels of ER, PgR, pAKT, pERK1/2, EGFR, epir, amphir or neur were associated with Ki67 response (p > 0.20). However, HER3 (p = 0.01) and HER2 (p = 0.06) mRNA levels were associated with greater Ki67 response. There was a tendency for Ki67 response to be greater with lower baseline Ki67 (p = 0.07). Multivariate analysis showed only HER3 mRNA levels to be independently significant. HER2 and HER3 mRNA levels were highly correlated (rho = 0.67, p < 0.001), a relationship confirmed in 2 other datasets (Wang et al, Breast Cancer Res, 2011, 13, R92; Dunbier et al, submitted). All Ki67 responders were above the median for both HER3 and HER2 expression.
Conclusions: Lapatinib is antiproliferative in a subgroup of HER2− tumours. This exploratory analysis indicates that they are characterized by high HER3 expression. The possible importance of high HER2:HER3 heterodimers in predicting this response is supported by the relationship between HER2 and HER3 expression. Further exploration of lapatinib is merited in HER2− cases with high HER3 expression.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD07-07.
Collapse
Affiliation(s)
- M Dowsett
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - A Leary
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - A Evans
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - R A'Hern
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - J Bliss
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - R Sahoo
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - S Detre
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - M Hills
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - B Haynes
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - C Harper-Wynne
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - N Bundred
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - G Coombes
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - IE Smith
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| | - S Johnston
- Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom
| |
Collapse
|
5
|
Johnston S, Kilburn L, Ellis P, Cameron D, Dodwell D, Howell A, Im Y, Coombes G, Dowsett M, Bliss J. 2LBA Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor – First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747). Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70687-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Larkin JMG, Turajlic S, Nathan PD, Lorigan P, Stamp G, Gonzalez de Castro D, Martin N, Griffiths J, Edmonds K, Sarker S, James MG, A'Hern R, Coombes G, Snowdon C, Bliss JM, Gore ME, Marais R. A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Treasure T, Bliss J, Tan C, Entwisle J, Waller D, O'Brien M, Coombes G, Webster-Smith M, Kilburn L, Snee M, Thomas G, Darlison L, Lang-Lazdunski L, Peto J. 53 Principal results of the feasibility phase of the Mesothelioma and Radical Surgery trial (MARS-feasibility). Lung Cancer 2011. [DOI: 10.1016/s0169-5002(11)70053-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Sirohi B, A'Hern R, Coombes G, Bliss JM, Hickish T, Perren T, Crawford M, O'Brien M, Iveson T, Ebbs S, Skene A, Laing R, Smith IE. A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. Ann Oncol 2010; 21:1623-1629. [PMID: 20093351 DOI: 10.1093/annonc/mdp602] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND The epirubicin with cisplatin and infusional 5-fluorouracil (5-FU) (ECisF) regimen was found to be highly active in the treatment of metastatic breast cancer and as neoadjuvant therapy. The UK TRAFIC (trial of adjuvant 5-FU infusional chemotherapy) trial (CRUK/95/007) compared this schedule with 5-FU, epirubicin and cyclophosphamide (FEC60) as adjuvant therapy in patients with early breast cancer. METHODS In this multicentre, open-label, phase III randomised controlled trial, 349 women were randomly assigned to receive i.v. ECisF [epirubicin 60 mg/m(2), day 1, cisplatin 60 mg/m(2), day 1 and 5-FU 200 mg/m(2) by daily 24-h infusion (n = 172)] or FEC [5-FU 600 mg/m(2), day 1, epirubicin 60 mg/m(2), day 1 and cyclophosphamide 600 mg/m(2), day 1 (n = 177)]. Both treatments were delivered every 3 weeks for six cycles. The primary end point was relapse-free interval (RFI). TRAFIC is registered as an International Standard Randomised Controlled Trial (ISRCTN 83324925). RESULTS All randomised patients were included in the intent-to-treat population. With a median follow-up of 112 months, there was no significant difference in RFI between the treatment groups [hazard ratio 0.84 (95% confidence interval 0.60-1.19); P = 0.33]. Toxic effects were more frequent in patients allocated to ECisF. CONCLUSIONS While limited by size, TRAFIC has long follow-up. No evidence of a clinically worthwhile benefit for the infusional treatment compared with standard treatment was observed which would justify further investigation or widespread use.
Collapse
Affiliation(s)
- B Sirohi
- Department of Medical Oncology, Max Cancer Centre, Max Healthcare, New Delhi, India (formerly at The Royal Marsden NHS Foundation Trust)
| | - R A'Hern
- ICR Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, Surrey
| | - G Coombes
- ICR Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, Surrey
| | - J M Bliss
- ICR Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, Surrey
| | - T Hickish
- Department of Oncology and Centre for Postgraduate Medical Research and Education, Institute of Cancer Research Clinical Trials and Statistics Unit, Royal Bournemouth Hospital, Bournemouth
| | - T Perren
- Non-Surgical Oncology, Institute of Cancer Research Clinical Trials and Statistics Unit, St James's University Hospital, Leeds
| | - M Crawford
- Medical Oncology, Airedale General Hospital, Keighley
| | - M O'Brien
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London & Sutton; Mid Kent Oncology Centre, Maidstone Hospital, Sutton, Surrey
| | - T Iveson
- Oncology Department, Pembroke Suite, Salisbury District Hospital, Salisbury
| | - S Ebbs
- Breast Unit, Mayday University Hospital, Croydon
| | - A Skene
- Department of Surgery, Institute of Cancer Research Clinical Trials and Statistics Unit, Royal Bournemouth Hospital, Bournemouth
| | - R Laing
- Department of Oncology, St Luke's Cancer Centre, Guildford, UK
| | - I E Smith
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London & Sutton.
| |
Collapse
|
9
|
Duffy N, Peckitt C, Coombes G, Tan C, Treasure T, Peto J. 59 The mesothelioma and radical surgery (MARS) trial update. Lung Cancer 2007. [DOI: 10.1016/s0169-5002(07)70385-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
|
11
|
Murchan S, Kaufmann ME, Deplano A, de Ryck R, Struelens M, Zinn CE, Fussing V, Salmenlinna S, Vuopio-Varkila J, El Solh N, Cuny C, Witte W, Tassios PT, Legakis N, van Leeuwen W, van Belkum A, Vindel A, Laconcha I, Garaizar J, Haeggman S, Olsson-Liljequist B, Ransjo U, Coombes G, Cookson B. Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant Staphylococcus aureus: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. J Clin Microbiol 2003; 41:1574-85. [PMID: 12682148 PMCID: PMC153895 DOI: 10.1128/jcm.41.4.1574-1585.2003] [Citation(s) in RCA: 531] [Impact Index Per Article: 25.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2002] [Revised: 10/10/2002] [Accepted: 12/18/2002] [Indexed: 11/20/2022] Open
Abstract
Pulsed-fieldgel electrophoresis (PFGE) is the most common genotypic method used in reference and clinical laboratories for typing methicillin-resistant Staphylococcus aureus (MRSA). Many different protocols have been developed in laboratories that have extensive experience with the technique and have established national databases. However, the comparabilities of the different European PFGE protocols for MRSA and of the various national MRSA clones themselves had not been addressed until now. This multinational European Union (EU) project has established for the first time a European database of representative epidemic MRSA (EMRSA) strains and has compared them by using a new "harmonized" PFGE protocol developed by a consensus approach that has demonstrated sufficient reproducibility to allow the successful comparison of pulsed-field gels between laboratories and the tracking of strains around the EU. In-house protocols from 10 laboratories in eight European countries were compared by each center with a "gold standard" or initial harmonized protocol in which many of the parameters had been standardized. The group found that it was not important to standardize some elements of the protocol, such as the type of agarose, DNA block preparation, and plug digestion. Other elements were shown to be critical, namely, a standard gel volume and concentration of agarose, the DNA concentration in the plug, the ionic strength and volume of running buffer used, the running temperature, the voltage, and the switching times of electrophoresis. A new harmonized protocol was agreed on, further modified in a pilot study in two laboratories, and finally tested by all others. Seven laboratories' gels were found to be of sufficiently good quality to allow comparison of the strains by using a computer software program, while two gels could not be analyzed because of inadequate destaining and DNA overloading. Good-quality gels and inclusion of an internal quality control strain are essential before attempting intercenter PFGE comparisons. A number of clonally related strains have been shown to be present in multiple countries throughout Europe. The well-known Iberian clone has been demonstrated in Belgium, Finland, France, Germany, and Spain (and from the wider HARMONY collection in Portugal, Slovenia, and Sweden). Strains from the United Kingdom (EMRSA-15 and -16) have been identified in several othercountries, and other clonally related strains have also been identified. This highlights the need for closer international collaboration to monitor the spread of current epidemic strains as well as the emergence of new ones.
Collapse
Affiliation(s)
- Stephen Murchan
- Laboratory of Hospital Infection, Central Public Health Laboratory, London NW9 5HT, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Wils JA, Bliss JM, Marty M, Coombes G, Fontaine C, Morvan F, Olmos T, Pérez-López FR, Vassilopoulos P, Woods E, Coombes RC. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. J Clin Oncol 1999; 17:1988-98. [PMID: 10561249 DOI: 10.1200/jco.1999.17.7.1988] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To assess whether the addition of epirubicin (EPI) therapy to prolonged treatment with tamoxifen (TAM) improves relapse-free and overall survival in postmenopausal women with node-positive primary breast cancer. PATIENTS AND METHODS Six hundred four patients entered onto a randomized clinical trial were allocated to receive TAM 20 mg/d for 4 years or TAM 20 mg/d for 4 years plus EPI 50 mg/m(2) intravenously on days 1 and 8 every 4 weeks for six cycles. Analysis was performed according to allocated treatment, with all randomized patients included (intention to treat), irrespective of eligibility status. RESULTS After a median follow-up period of 5.7 years, an improvement in relapse-free survival (RFS) was observed for the TAM and EPI-treated patients, compared with those who received TAM alone. The unadjusted hazard ratio was 0.72 (95% confidence interval, 0.54 to 0.96), with a corresponding reduction in the odds of recurrence of 27.9% (SD, 12. 3), which was statistically significant (P =.023). Adjustment for prognostic and/or predictive factors did not materially affect the hazard ratio. No difference was observed in terms of overall survival (reduction in odds of death, 11.9% [SD, 16.3]; P =.46). Combined chemohormonal treatment was associated with a higher incidence of acute side effects but without a clear increase in long-term cardiotoxicity. Twelve nonbreast second malignancies, including five hematologic malignancies (two of which were cases of acute myelogenous leukemia), were observed. CONCLUSION The data show that combined chemohormonal treatment reduces the risk of relapse in postmenopausal patients with node-positive breast cancer. No evidence was found, however, for an improvement in overall survival. The size of benefit observed for both outcomes was consistent with that reported in the Early Breast Cancer Trialists' Collaborative Group overview. The trial presented here, however, provides the first report of an improvement in RFS associated with the provision of a single cytotoxic drug in addition to prolonged TAM.
Collapse
Affiliation(s)
- J A Wils
- Laurentius Hospital, Roermond, The Netherlands
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
We studied four treatment regimens of oral alendronate in 60 patients with active Paget's disease. Two groups received an oral daily dose of either 40 or 80 mg of alendronate for 3 months, followed by placebo for a further 3 months: the other two groups received treatment with 40 or 80 mg per day for 6 months. Activity of alkaline phosphatase and urinary hydroxyproline excretion were measured before, during, and after treatment, at intervals for a total follow-up of 1 year. A transiliac bone biopsy was performed in 24 patients before and after the treatment. An additional 16 patients had a third biopsy more than a year after stopping treatment. Alendronate induced a marked suppression in the urinary excretion of hydroxyproline within 2 weeks (p < 0.01) followed by a fall in serum activity of alkaline phosphatase at 1 month (p < 0.01) in all treatment groups. Nine months after the start of treatment patients treated with 80 mg for 6 months had a significantly lower mean alkaline phosphatase activity compared to the other treatment groups (p < 0.02), which persisted at 1 year (p < 0.05). Alkaline phosphatase decreased to within the laboratory reference range in all patients given 80 mg for 6 months. In contrast, alkaline phosphatase decreased to within the laboratory reference range in 73-83% of patients given 80 mg for 3 months and the 40 mg dose. Histomorphometric assessment showed a decrease in indices of bone turnover in the pagetic biopsies. None of the biopsies taken after treatment showed evidence of impaired mineralization of bone. Gastrointestinal side effects occurred in 25% of patients of whom two withdrew from treatment. We conclude that oral alendronate is an effective agent for the treatment of Paget's disease of bone.
Collapse
Affiliation(s)
- S A Khan
- WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Khan SA, McCloskey EV, Eyres KS, Nakatsuka K, Sirtori P, Orgee J, Coombes G, Kanis JA. Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res 1996; 11:178-82. [PMID: 8822341 DOI: 10.1002/jbmr.5650110206] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We compared the effects of three different regimens of intravenous clodronate in a retrospective study of 60 patients with Paget disease. A total dose of 1500 mg of clodronate was given as 300 mg for 5 consecutive days (n = 20), 1500 mg as a single infusion (n = 20), or 300 mg as a single infusion for 5 consecutive months (n = 20). The response to treatment and the duration of the effect were assessed from sequential changes in the activity of serum alkaline phosphatase. Treatment with clodronate induced a significant response in 85% of patients. The response rate was comparable in patients treated with 5 daily infusions (90%), with a single infusion (75%), and with 5 monthly infusions (90%). The median duration of response from the start of treatment was 11 months for those treated with five daily infusions and 12 months for the other two regimens. At one year, 22, 40, and 44% of patients had maintained their response in the daily, single, and monthly infusion regimen, respectively (NS). Six patients (32%) treated with 5 daily infusions achieved a remission (complete response) compared with 3 patients treated with a single infusion and 5 monthly infusions, respectively (16 and 15% respectively, NS). Patients attaining a complete response had a significantly longer duration of response compared with partial responders (median time 15.0 versus 11.5 months, respectively, p < 0.05). We conclude that intravenous clodronate (total dose 1500 mg) suppresses disease activity in the majority of patients with Paget disease of bone. The degree and duration of response were similar for the three regimens. Thus, in the treatment of Paget disease, the choice of regimen is a matter of convenience.
Collapse
Affiliation(s)
- S A Khan
- Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, United Kingdom
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Coombes RC, Bliss JM, Wils J, Morvan F, Espié M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Pérez-López FR, Vassilopoulos P, Ferreira EP, Chilvers CE, Coombes G, Woods EM, Marty M. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 1996; 14:35-45. [PMID: 8558217 DOI: 10.1200/jco.1996.14.1.35] [Citation(s) in RCA: 127] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
PURPOSE To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer. PATIENTS AND METHODS The International Collaborative Cancer Group (ICCG) conducted a large randomized trial in which two alternative schedules were used according to participating center: CMF1 versus FEC1 and CMF2 versus FEC2. RESULTS Seven hundred fifty-nine patients were entered onto the trial. At a median follow-up time of 4.5 years, no significant benefit for the anthracycline-containing regimen was observed in terms of relapse-free (P = .61) or overall survival (P = .13). FEC1 and CMF1 appear to be of similar efficacy, but there is a suggestion that FEC2 may be superior to CMF2, since patients who received FEC2 had improved overall (P = .02) and relapse-free survival (P = .03) rates. Nausea and vomiting and alopecia were more common in the epirubicin-containing regimen (P = .001). CONCLUSION We conclude that the FEC2 regimen, in which epirubicin replaced the methotrexate in CMF, is the preferable adjuvant chemotherapy regimen for premenopausal patients with operable axillary node-positive breast cancer.
Collapse
Affiliation(s)
- R C Coombes
- Medical Oncology Unit, Charing Cross Hospital, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
We assessed a method for the measurement of ultrasound velocity in cortical bone of the human tibia using a probe designed to minimize the effects of surrounding soft tissues. Of four different measurement values, the maximum velocity (average of the five highest readings) gave the lowest errors of reproducibility in relation to the population variance (standardized coefficient of variation = 1.8%). The maximum velocity varied according to the tibial site measured and for practical reasons the mid-tibial site was chosen for further study. The short-term intra- and inter-observer reproducibilities (coefficients of variation) were 0.35% (n = 22) and 0.50% (n = 27) respectively. Long-term reproducibility over 4 months in 31 subjects was 0.68%. There was no significant difference in maximum ultrasound velocity between the dominant and nondominant tibia in 78 women (3764 +/- 209 vs 3763 +/- 199 m/s). Tibial ultrasound velocity was significantly higher in 73 premenopausal women (3999 +/- 102 m/s) than in 129 women referred for assessment of postmenopausal osteoporosis (3780 +/- 168 m/s), 26 women with steroid-induced osteoporosis (3790 +/- 188 m/s) and 4 women with hyperparathyroidism (3575 +/- 261 m/s). In premenopausal women, ultrasound velocity did not correlate significantly with age, height, weight or body mass index. In women with postmenopausal osteoporosis, ultrasound velocity decreased with age after the menopause (r = -0.47, p < 0.0001) and body weight exerted a weaker protective effect. The apparent annual decrease in velocity with age in postmenopausal osteoporosis (8.5 m/s) was comparable to the error of reproducibility. We conclude that the technique for measuring tibial ultrasound velocity is highly reproducible in relation to the distribution of values in the population and is sensitive to age- and osteoporosis-induced changes in bone. Further studies are required to examine its relationship to other indices of skeletal status to determine the biological and clinical relevance of the technique.
Collapse
Affiliation(s)
- J M Orgee
- Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, UK
| | | | | | | | | | | |
Collapse
|